–
Lara Pharm is developing the active ingredient in cannabis to work in an inhaler.
–
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
–
Therapix Biosciences Ltd. (TASE: TRPH) (formerly NasVax) share price jumped 16.85% today to $0.17 on news that it is to acquire medical cannabis developer Lara Pharm Ltd.
In the first stage Therapix invested $800, 000 for 26% of Lara Pharm. The company is now buying a further 49% for $1.5 million.
Lara Pharm is developing a formulation of THC, the active ingredient in cannabis, to work in an inhaler.
Published by Globes [online], Israel business news – www.globes-online.com – on August 11, 2014
